EUVIMEDEUVIMED entdecken
Open Access

Self-inactivating AAV-CRISPR at different ages enables sustained amelioration of Huntington’s disease deficits in BAC226Q mice

Yuanyi Dai iD, Zuliayeti Abudujielili iD, Yunyi Ding, Wanping Huang, Jianhang Yin, Liqiong Ou iD, Jiazhi Hu iD, Sushuang Zheng iD, Chenjian Li iD

Science Advances · 2026

DOI: 10.1126/sciadv.aea8052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Yuanyi Dai und 8 weiteren Autor:innen. Beteiligte Einrichtung: The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China. Hauptthemen laut MEDLINE: Huntington Disease, Huntingtin Protein, CRISPR-Cas Systems, Dependovirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: SLS-Qidong Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huntington’s disease (HD) is a monogenic autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the HTT gene, yielding a gain-of-toxic-function mutant Huntingtin protein (mHTT). CRISPR-Cas9 is a potentially powerful therapeutic strategy for HD by eliminating mutant HTT (m HTT ) gene. We developed a specific SaCas9 guide RNA to target human m HTT and a self-inactivating gene editing system that abolishes SaCas9 after a short transient expression for high gene editing efficiency and maximal safety to prevent off-target effects. Both conventional and the self-inactivating gene editing systems successfully eliminated m HTT gene, 60 to 90% mHTT protein and 90% of mHTT aggregation in BAC226Q mouse brains, which resulted in significant long-term rescue of neuropathology, motor deficits, weight loss, and shortened life span. These beneficial effects were observed when gene editing was applied before, at, and well after the onset of pathological and behavioral abnormalities. These proof-of-concept data demonstrate that gene editing can be a highly effective therapeutic approach for HD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseHuntingtin ProteinCRISPR-Cas SystemsDependovirusGene EditingAnimalsMiceHumansDisease Models, AnimalGenetic TherapyChromosomes, Artificial, BacterialMice, Transgenic

Substanzen

Huntingtin Protein

Autor:innen und Institutionen

  • The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China.

ORCID-Profile: Yuanyi Dai, Zuliayeti Abudujielili, Liqiong Ou, Jiazhi Hu, Sushuang Zheng, Chenjian Li

Förderung

  • SLS-Qidong Innovation Fund

Zitieren

APA

Dai, Y., Abudujielili, Z., Ding, Y., Huang, W., Yin, J., Ou, L., Hu, J., Zheng, S., & Li, C. (2026). Self-inactivating AAV-CRISPR at different ages enables sustained amelioration of Huntington’s disease deficits in BAC226Q mice. Science Advances. https://doi.org/10.1126/sciadv.aea8052

Vancouver

Dai Y, Abudujielili Z, Ding Y, Huang W, Yin J, Ou L, et al. Self-inactivating AAV-CRISPR at different ages enables sustained amelioration of Huntington’s disease deficits in BAC226Q mice. Science Advances. 2026. doi:10.1126/sciadv.aea8052

BibTeX
@article{Dai2026,
  author = {Dai, Yuanyi and Abudujielili, Zuliayeti and Ding, Yunyi and Huang, Wanping and Yin, Jianhang and Ou, Liqiong and Hu, Jiazhi and Zheng, Sushuang and Li, Chenjian},
  title = {Self-inactivating AAV-CRISPR at different ages enables sustained amelioration of Huntington’s disease deficits in BAC226Q mice},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aea8052}
}
Kostenlos starten →